Tyme Technologies Inc

Tyme Technologies — Investor Presentation (July 2017)

23 slides from Tyme Technologies's investor presentation, Jul 13, 2017

  1. Slide 1: TYME for something new

    ”, TYMEQ) TYME for something new July 2017

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements in this presentation and associated oral statements are “forward-looking statements.” These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risk factors and uncertainties that could cause actual resu

  3. Slide 3: Tyme Overview

    Tyme Overview PRINCIPLE RESULTS SVAN’ STATUS Attack cancer through its natural function rather than attempting to change it Use cancer's metabolic cycle as a universal entry point Complete and partial responses with 13 different cancer types in metastatic setting Duration in some patients maintained

  4. Slide 4: Corporate History

    Corporate History 2008-2014 2015-2016 2017+ Charitable Mission Corporate Formation Growth & Expansion + Virtual company funded by + First outside funding + Expansion of executive founders team, Board and operations * Launched Phase Ib/II + Mission to help patients that prostate trial under Tyme IND.

  5. Slide 5: Senior Management

    Senior Management Steve Hoffman: Co-Founder, Chief Executive and Chief Science Officer + >30 years of experience in biochemistry and physics; lead author on over 40 patents + Focused on biopharmaceuticals for oncology, metabolic syndrome and central nervous system + Previously involved in chemistry,

  6. Slide 6: Non-Executive Directors and Advisory Board

    Non-Executive Directors and Advisory Board Non-Executive Board of Directors Dr. Gerald Sokol >30 years as distinguished oncologist and 27 years as FDA reviewer in oncology division eid Carter) Chair of audit committee: >40 years in finance, primarily at J&J >30 years in pharma industry with executiv

  7. Slide 7: Two separate phenomena found across all cancers

    Two separate phenomena found across all cancers Warburg Effect Mucin Coating * Discovered in the 1920s * Protective layer that encircles cancer cells ¢ Shows that cancer produces energy differently than normal * Protects the cancer from external cells influences, like the immune system * Relies on a

  8. Slide 8: Breaking the Metabolic Circuit of Cancer

    Breaking the Metabolic Circuit of Cancer 2) Protein Synthesis Fails, Ne 1) Induce Uptake of TYME's Dysfunctional ia >) 3) Protective Mucin Tyrosine hee Y Layer Compromised 7 4) Cell Death From Oxidative Stress Immune Response

  9. Slide 9: Disrupts cancer's creation of proteins

    Disrupts cancer’s creation of proteins, including mucin Increases tyrosine uptake Dysfunctional Tyrosine Derivative Rapamycin Causes the production of more free radicals Phenytoin Methoxsalen Facilitates cell death through oxidative stress

  10. Slide 10: Clinical Development Pipeline

    Clinical Development Pipeline Cancer Indicat Pre-IND Phase 1 Phase 2 Phase 3 Prostate, recurrent non-metastatic Pancreatic, metastatic 7 Metastatic cancers L MYfrrrxposyyy VM UMMM. Injectable caemie aula Glioma Breast Various cancers Non-invasive radiosurgery TYME

  11. Slide 11: Historical Results Directing Clinical Plan

    Historical Results Directing Clinical Plan CR/PR Shown in 13 Different Tumor Types esponse Total Estimated Metastatic Incidence Deaths 5-Year Survival Current Clinical Programs at 161k 27k 29% v S creatic 54k 43k 1% v v Breast 255k 4lk 22% v v ft Tissue 12k 5k 16% v v in 223k 156k 1% v Brair 24k 17k

  12. Slide 12: SM-88: First Human Study (FHS)

    SM-88: First Human Study (FHS) Population Treatment Monotherapy with SM-88 - Cycle: Five doses per week, oral and injection, for six weeks - Average treatment of 16.3 weeks * Enrolled 30 patients during 2012 + End-stage metastatic cancer - Expected survival 3-6 months - Failed or refused all availab

  13. Slide 13: SM-88: FHS Progression Free Survival

    SM-88: FHS Progression Free Survival All Subjects (n = 30), Monotherapy with SM-88 Only 10% of subjects experienced a quantifiable disease progression Other subjects: 2 complete and 6 partial responses, 19 stable disease (RECIST criteria) Median PFS of 14.7 months Study Ended Without © 73% Disease P

  14. Slide 14: SM-88: FHS Progression Free Survival

    SM-88: FHS Progression Free Survival Subgroup Analysis Where Penultimate PFS Available (n = 23) Median SM-88 PFS: 11 months Breast Breast 2.1x longer PFS on SM-88 than last therapy prior to SM-88 Statistically significant p- value of <0.05 » Study Ended Without Disease Progression 1512 Death Without

  15. Slide 15: SM-88: FHS efficacy examples

    SM-88: FHS pelecice ENIEGCY examples + Achieved long durations of survival in some of the cancers that are hardest to treat and with poor prognosis + Effective in triple negative breast cancer, NSCLC and pancreatic cancer M Example # Gases Prior Therapy | Penultimate PFS S (2) Os (2) Cancer Type Bre

  16. Slide 16: SM-88: First Human Study Overall Survival

    SM-88: First Human Study Overall Survival All Subjects (n = 30), Monotherapy with SM-88 100 W survival Rate (¥) 20.0 0.00 T T T T T T ° 5 10 as 20 25 30 3-6m expected OS 50% SM-88 OS: 47% ECOG PS 22 25.7 months TYMEO | +6

  17. Slide 17: SM-88: First Human Study Safety Profile

    SM-88: First Human Study Safety Profile Median SM-88 exposure: 16.3 weeks, (range: 6-61 weeks) Adverse Events Reported in the First Human Study (n=30)' Adverse Event Adverse Event | Grade 1 | Grade2 Grade 3/4 Total rpi 29 (97%) 1 (3%) = 30 (100%) 13 (43%) 4 (13%) E 17 (57%) 3 (10%) 1 (3%) = 4 (13%)

  18. Slide 18: Current and Planned Trials

    Current and Planned Trials

  19. Slide 19: Phase 1b/2 Non-Metastatic Prostate Cancer

    Phase 1b/2 Non-Metastatic Prostate Cancer rim Clinical Data _ Phase 1b/2 Open-Label Study to Evaluate Safety and Efficacy in Biomarker-Recurrent, Non-Metastatic Prostate Cancer IND filed May 2016 Phase 1b: dose-escalation phase (n=4), completed January 2017 Phase 2: rising prostate specific antigen

  20. Slide 20: Phase 1b/2 Non-Metastatic Prostate Cancer Interim Data

    Phase 1b/2 Non-Metastatic Prostate Cancer Interim Clinical Data Presented at ASCO June 5, 2017 of Ongoing Phase 1b/2 Trial in Biomarker Recurrent Prostate Cancer Evaluable subject response (n=8) 100.0% 87.5% None All subjects All subjects

  21. Slide 21: Planned Phase 2 Trial Design: Metastatic Pancreas Cancer

    Planned Phase 2 Trial Design: Metastatic Pancreas Cancer Indication: Refractory metastatic pancreatic cancer (2L/3L) Therapy: Monotherapy with SM-88, single arm CRO: Quintiles/Novella Sites: ~35 across North America Enrollment: Initial 30 subjects, expandable to 120 Design: Open-label, with planned

  22. Slide 22: Rationale for Metastatic Pancreas Cancer

    Rationale for Metastatic Pancreas Cancer * Current prognosis for pancreatic cancer is 80% mortality in first year!) + Standard-of-care results from recent clinical trials: - First-line Abraxane + gemcitibine: median OS of 8.5m and CR+PR of 23% - — First-line FOLFIRINOX: OS of 11m and CR+PR of 31% -

  23. Slide 23: Recent Achievements and Upcoming Objectives

    Recent Achievements and Upcoming Objectives Recent Achievements Upcoming Objectives v Positive interim Phase 1b/2 prostate cancer data published v¥ Four additional data publications at ASCO 2017 v Preclinical toxicology data released at ESMO 2016 ¥ Two core platform patents issued ¥ Raised funding f

Tyme Technologies — Investor Presentation (July 2017) on 6ix